☆ 4.7 Meeting Abstract

Final overall survival (OS) for abemaciclib plus trastuzumab plus /- fulvestrant versus trastuzumab plus chemotherapy in patients with HR+, HER2+advanced breast cancer (monarcHER): A randomized, open-label, phase II trial

ANNALS OF ONCOLOGY (2022)

Get Full Text
Add to Collection

Journal

ANNALS OF ONCOLOGY
Volume 33, Issue 7, Pages S1386-S1387

Publisher

ELSEVIER
DOI: 10.1016/j.annonc.2022.08.013

Keywords

-

Categories

Oncology

Funding

  1. Eli Lilly and Company

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.